Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Autoimmune Disease

NCT06375993 is registered in ClinicalTrials.gov with Adicet Therapeutics as lead sponsor.

NCT NCT06375993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06375993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Autoimmune Disease
Lead sponsor
Adicet Therapeutics
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
November 10, 2024
Completion date
December 31, 2027
Enrollment
180 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis (aav), autoimmune diseases, idiopathic inflammatory myopathies, lupus nephritis, stiff person syndrome, systemic lupus erythematosus (sle), systemic sclerosis (ssc)